


EMLc

ATC codes: [L01CA02](#)

Indication	Retinoblastoma <span>ICD11 code: <a href="#">2D52.2</a></span>
INN	Vincristine
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)
EML status history	First added in 2015 ( <a href="#">TRS 994</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 

Tags

Cancer

Wikipedia

[Vincristine](#) 

DrugBank

[Vincristine](#) 

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.

[Expert Committee report](#) 

